[1]后亚芳,刘 园,陆晨曦,等.冠心舒通胶囊调节PI3K/AKT/mTOR信号通路保护H9c2心肌细胞机制研究[J].陕西中医,2025,46(3):296-300.[doi:DOI:10.3969/j.issn.1000-7369.2025.03.002]
　HOU Yafang,LIU Yuan,LU Chenxi,et al.Guanxin Shutong capsule treats damage protection mechanism of H9c2 cardiomyocytes through PI3K/AKT/mTOR pathway[J].,2025,46(3):296-300.[doi:DOI:10.3969/j.issn.1000-7369.2025.03.002]
点击复制

冠心舒通胶囊调节PI3K/AKT/mTOR信号通路保护H9c2心肌细胞机制研究
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
46
期数:
2025年3期
页码:
296-300
栏目:
基础研究
出版日期:
2025-03-05

文章信息/Info

Title:
Guanxin Shutong capsule treats damage protection mechanism of H9c2 cardiomyocytes through PI3K/AKT/mTOR pathway
作者:
后亚芳1; 刘 园2; 陆晨曦2; 段婷婷2; 任菲菲2; 杜 霞2
(1.陕西中医药大学,陕西 咸阳 712046; 2.陕西省中医药研究院,陕西 西安 710003)
Author(s):
HOU Yafang1; LIU Yuan2; LU Chenxi2; DUAN Tingting2; REN Feifei2; DU Xia2
(1.Shaanxi University of Chinese Medicine,Xianyang 712046,China; 2.Shaanxi Academy of Traditional Chinese Medicine,Xi'an 710003,China)
关键词:
冠心病;  冠心舒通胶囊;  H9c2心肌细胞;  H/R模型;  PI3K/AKT/mTOR信号通路;  心肌损伤
Keywords:
Coronary heart disease;  Guanxin Shutong capsule;  H9c2 cardiomyocytes;  Hypoxia-ischemia model;  PI3K/AKT/mTOR signaling;  Myocardial injury
分类号:
R 256
DOI:
DOI:10.3969/j.issn.1000-7369.2025.03.002
文献标志码:
A
摘要:
目的:本研究探讨冠心舒通胶囊基于PI3K/AKT/mTOR通路防治H9c2心肌细胞缺氧/复氧损伤(H/R)的作用机制。方法:建立H9c2心肌细胞H/R模型,分为对照组、模型组、冠心舒通胶囊不同浓度组。采用PI染色法(PI)和酶标法测定乳酸脱氢酶(LDH)活性、肌酸激酶同工酶(CK-MB)含量评价模型。冠心舒通胶囊组采用梯度浓度对细胞进行预给药处理,采用CCK-8法测定细胞活性,酶标法测定LDH活性、CK-MB含量,并通过实时荧光定量PCR(RT-qPCR)法检测磷酸肌醇3-激酶(PI3K)、蛋白激酶B(AKT)、哺乳动物雷帕霉素靶蛋白(mTOR)的mRNA水平。结果:CCK-8法筛选出缺氧8、16 h细胞用于后续实验检测。PI染色4、8 μg/ml 冠心舒通胶囊组细胞活性在60%～75%; 与模型组相比,经冠心舒通胶囊干预后H/R H9c2心肌细胞活性显著提升,而LDH活性、CK-MB含量降低,PI3K、AKT、mTOR的mRNA表达降低。结论:冠心舒通胶囊通过调节PI3K/AKT/mTOR信号通路抑制H9c2细胞损伤,对H/R造成的心肌损伤具有一定保护作用。
Abstract:
Objective:To investigate mechanism of Guanxin Shutong capsule in prevention and treatment of hypoxia reoxygenation cardiomyocytes(Hypoxia/Reoxygenation,H/R)based on PI3K/AKT/mTOR pathway.Methods:H9c2 cardiomyocyte H/R model was established and randomly divided into control group,model group and Guanxin Shutong capsule group with different concentration.The model was evaluated by PI staining method,enzyme labelling to determine lactate dehydrogenase(LDH)activity and creatine kinase isoenzymes(CK-MB)content.Guanxin Shutong capsule group were treated with gradient concentration of pre-administration of cells,cell viability determined by cell counting kit-8(CCK-8),LDH activity and CK-MB content determined by enzymatic hydrogenase method.The mRNA levels of Phosphatidylinositol 3-kinase(PI3K),protein kinase B(AKT)and mechanistic target of rapamycin(mTOR)were detected by RT-qPCR.Results:Cells with 8 h and 16 h of hypoxia were screened by CCK-8 method for follow-up test.The cell viability of the 4 μg/ml and 8 μg/ml Guanxin Shutong capsule groups stained by PI was 60%～75%.Compared with the model group,after intervention of Guanxin Shutong capsule,the viability of H9c2 cardiomyocytes were significantly improved,LDH activity and CK-MB content reduced,and mRNA expressions of PI3K,AKT and mTOR significantly decreased.Conclusion:Guanxin Shutong capsule can inhibit injury of H9c2 cells by regulating PI3K/AKT/mTOR signaling pathway,and has certain protective effect on myocardial injury caused by hypoxia/reoxygenation.

参考文献/References:

[1] 吉锋,李展绒,任耀龙,等.化痰通瘀除痹方治疗冠心病合并颈动脉粥样硬化斑块痰瘀困阻证疗效研究[J].陕西中医,2022,43(9):1212-1214.
[2] 王勇花,李欣彤,周靖雅,等.冠心病主要危险因素的研究进展[J].新疆中医药,2023,41(3):137-140.
[3] 俞婷婷,钱涛铭,邹国良,等.国医大师卢芳论治冠心病的临床经验[J].中国中医急症,2024,33(9):1654-1656,1660.
[4] 王晓,刘博,张译心,等.黄连总生物碱与三七皂苷组合物对大鼠糖尿病心肌缺血再灌注损伤的影响[J].中南药学,2021,19(6):1092-1097.
[5] 王健.冠心舒通胶囊对大鼠心肌缺血再灌注损伤细胞凋亡影响的实验研究[D].沈阳:辽宁中医药大学,2014.
[6] 贾敏.羟基红花黄色素A通过PI3K/Akt/Hexokinase Ⅱ途径在缺氧/复氧诱导的H9c2心肌细胞损伤中的保护机制研究[D].石家庄:河北医科大学,2017.
[7] 余福林,高延,王利,等.PI3K/Akt信号参与介导虎杖甙对缺血/再灌注心肌的保护作用[J].心脏杂志,2022,34(4):373-377,388.
[8] 方欢乐,周亚明,陈衍斌.冠心舒通胶囊防治心血管疾病研究进展[J].中国医药导报,2022,19(25):47-50.
[9] 崔鑫,韩晟,李军,等.冠心舒通胶囊治疗冠心病心绞痛心血瘀阻证的临床综合评价[J].中国中药杂志,2022,47(6):1469-1475.
[10] 王雅琴,张艳,张伟.冠心舒通胶囊治疗心血瘀阻型冠心病心力衰竭的临床疗效[J].中国实验方剂学杂志,2023,29(7):153-159.
[11] 史航.冠心舒通胶囊联合美托洛尔治疗冠心病稳定型心绞痛的疗效及对血脂、hs-CRP的影响[J].辽宁中医杂志,2022,49(9):137-140.
[12] ZHU J,ZHOU H,LI C,et,al.Guanxin Shutong capsule ameliorates cardiac function and architecture following myocardial injury by modulating ventricular remodeling in rats[J].Biomed Pharmacother,2020,130:110527.
[13] 毛慧子,田洪阳.冠心舒通胶囊对缺血再灌注大鼠心肌细胞凋亡的影响[J].锦州医科大学学报,2018,39(4):12-14,116.
[14] 方欢乐,刘峰,韩宁娟,等.冠心舒通胶囊抑制TGF-β/Smad信号通路改善异丙肾上腺素诱导的大鼠心脏重塑机制研究[J].中药新药与临床药理,2019,30(5):516-522.
[15] 卢玉润,唐宇帆.肉桂对慢性缺氧心肌细胞的保护作用研究[J].陕西中医,2021,42(6):802-805.
[16] 陆培培,郭彩霞,马杰,等.心复力颗粒诱导缺氧无血清条件下H9c2心肌细胞自噬发挥抗凋亡作用的实验研究[J].中西医结合心脑血管病杂志,2020,18(5):745-750.
[17] 崔鑫,韩晟,李军,等.冠心舒通胶囊治疗冠心病心绞痛心血瘀阻证的临床综合评价[J].中国中药杂志,2022,47(6):1469-1475.
[18] 郏丽丽,陈艳.丹斛通痹汤对2型糖尿病合并冠心病心绞痛患者糖脂代谢和心功能改善作用的研究[J].中华全科医学,2025,23(2):248-252.
[19] 王哲.芦荟苷在心肌缺血再灌注损伤中的保护作用及机制研究[D].长春:吉林大学,2023.
[20] HU B,ZHANG Y,JIA L,et al.Binding of the pathogen receptor HSP90AA1 to avibirnavirus VP2 induces autophagy by inactivating the Akt-MTOR pathway[J].Autophagy,2015,11(3):503-515.
[21] 李想,李安特,孙秋霞,等.PI3K/AKT信号通路与神经损伤修复的研究进展[J].中国老年学杂志,2023,43(1):246-249.
[22] 李丹,滕红丽,覃裕旺,等.基于PI3K/AKT/mTOR信号通路探讨27nt-miRNA对血管平滑肌细胞自噬的调控作用[J].中国临床药理学杂志,2020,36(2):137-141.
[23] GIUSEPPINA C,ZEIN M B,EVELINA M,et al.The miR-139-5p regulates proliferation of supratentorial paediatric low-grade gliomas by targeting the PI3K/AKT/mTORC1 signaling[J].Neuropath Appl Neuro,2018,44(11):687-706.
[24] GUO Y,PEI X.Tetrandrine-induced autophagy in MDA-MB-231 Triple-Negative breast cancer cell through the inhibition of PI3K/AKT/mTOR signaling[J].Evid Based Complement Alternat Med,2019:7517431.
[25] KIM J,JUNG K H,RYU H W,et,al.Apoptotic effects of xanthium strumarium via PI3K/AKT/mTOR pathway in hepatocellular carcinoma[J].Evid Based Complement Alternat Med,2019:2176701.
[26] 褚盛楠,郭艳.PI3K/Akt/mTOR信号通路与肾缺血再灌注损伤相关性的研究进展[J].中国现代医生,2024,62(2):104-107.

相似文献/References:

[1]朱 薇.通脉调脂方治疗冠心病稳定性心绞痛疗效及对患者血流变、VCAM1〖JZ〗及ICAM1影响的研究*[J].陕西中医,2019,(3):290.
　ZHU Wei..Effect of Tongmai Tiaozhi recipe on the efficacy, Hemorheology, VCAM1 and ICAM1 〖JZ〗in patients with stable angina pectoris of coronary heart disease[J].,2019,(3):290.
[2]时晓华.丹参多酚酸盐注射液辅助介入治疗冠心病 及对患者心、肾功能和心肌损伤的影响*[J].陕西中医,2019,(5):568.
　SHI Xiaohua..Effects of salvianolate injection on cardiac function, renal function, myocardial injury in percutaneous coronary intervention postoperative patients with coronary heart disease[J].,2019,(3):568.
[3]刘 红,张玲燕,杨 玲.血府逐瘀汤治疗冠心病介入术后心绞痛临床研究[J].陕西中医,2019,(5):594.
　LIU Hong,ZHANG Lingyan,YANG Ling..Clinical observation of Xuefu Zhuyu decoction in the treatment of angina pectoris after PCI for coronary heart disease[J].,2019,(3):594.
[4]吕永飞,陈爱莲.益心康泰胶囊治疗冠心病经皮冠状动脉介入术术后疗效及对患者血流变、血管内皮功能的影响*[J].陕西中医,2019,(6):714.
　LV Yongfei,CHEN Ailian..Effect of Yixin Kangtai capsule on the curative effect hemorheology and vascular endothelial function after coronary artery disease PCI[J].,2019,(3):714.
[5]贺建涛,胡宇才,刘 磊.活血通络散治疗冠心病PCI术后心绞痛疗效研究*[J].陕西中医,2019,(7):854.
　HE Jiantao,HU Yucai,LIU Lei..Efficacy observation of Huoxue Tongluo powder in the treatment of angina pectoris after coronary heart disease PCI[J].,2019,(3):854.
[6]解洪涛,张 顺△,曾广伟.当归补血方联合西药治疗冠脉搭桥术后疗效及对患者血瘀证证候评分和凝血功能的影响*[J].陕西中医,2019,(10):1341.
　XIE Hongtao,ZHANG Shun,ZENG Guangwei..Effects of Danggui Buxue prescription combined with western medicine on blood stasis and coagulation function after coronary artery bypass grafting[J].,2019,(3):1341.
[7]索晓菲,王亚红△,王居新,等.软坚通脉汤治疗冠心病PCI术后Ⅱ期心脏康复疗效〖JZ〗及对患者生活质量的影响*[J].陕西中医,2020,(1):29.
[8]尹 毅,李小兰△.益气活血汤联合尼可地尔治疗稳定性心绞痛疗效及对患者T淋巴细胞亚群的影响[J].陕西中医,2020,(7):888.[doi:DOI:10.3969/j.issn.10007369.2020.07.014]
[9]季学清,刘 萍△,陈宝瑾,等.冠心康方加减联合西药治疗冠心病合并2型糖尿病气虚痰瘀证疗效研究*[J].陕西中医,2020,(9):1208.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.008]
　JI Xueqing,LIU Ping,CHEN Baojin,et al.Efficacy of Guanxinkang preparation combined with western medicine in the treatment of coronary heart disease and type 2 diabetes mellitus with syndrome of Qixu Tanyu[J].,2020,(3):1208.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.008]
[10]董其浩,邓 兵.益脉强心汤对冠心病合并心衰患者心室重构及血清血小板活化因子、转化生长因子-β1的影响[J].陕西中医,2021,(7):883.[doi:DOI:10.3969/j.issn.1000-7369.2020.07.018]

备注/Memo

备注/Memo:
[基金项目]国家自然科学基金青年科学基金资助项目(82204711); 陕西省中医药管理局“双链融合”中青年科研创新团队(2022-SLRH-YQ-003); 陕西省中医药管理局“医研校企”中医药传承创新平台(中医药创新药物/器械“研发-转化-推广”平台)项目
更新日期/Last Update: 2025-03-10